Biotech entity
All 3 tracked stories fall under one category: pharma. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. That works out to roughly 1.1 stories per week across a 20-day span. Their average consequence score of 6.7 runs above the beat's 6.1 for that window.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. That works out to roughly 1.1 stories per week across a 20-day span. Their average consequence score of 6.7 runs above the beat's 6.1 for that window. Each story carries 3 original sources on average, compared with 3.4 for the broader beat in this window. This profile follows 3 Biotech stories mentioning tirzepatide across the period from March 4, 2026 to March 23, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 289 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering tirzepatide. Shared-story counts are live from our verified record — not editorial picks.
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Eli Lilly has identified hazardous impurities in unapproved, compounded versions of its blockbuster weight-loss drugs, Mounjaro and Zepbound. The pharmaceutical giant is warning patients and providers about significant safety risks as compounding pharmacies continue to exploit ongoing supply shortages.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
tirzepatide is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
